DeciBio’s Post

How to evaluate the benefits of a #longevity intervention? Do I have to do a clinical trial with 80-year-old participants and wait 20 years to see how many become #centenarians? A few days ago, a review was published that has the makings of a landmark publication:   “With #geroscience research evolving at a fast pace, the need arises for human randomized controlled trials to assess the efficacy of geroprotective interventions to prevent #age-related adverse outcomes, disease, and mortality in normative #aging cohorts.   ❗However, to confirm efficacy requires a long-term and costly approach as time to the event of morbidity and mortality can be decades. While this could be circumvented using sensitive biomarkers of aging, current molecular, physiological, and digital endpoints require further validation.   In this review, we discuss how collecting #realworldevidence (RWE) by obtaining health data that is amenable for collection from large heterogeneous populations in a real-world setting can help speed up validation of geroprotective interventions.   ❗Further, we propose inclusion of quality of life (QoL) data as a biomarker of aging and candidate endpoint for geroscience clinical trials to aid in distinguishing healthy from unhealthy aging... Finally, we… present the short-form 36 (SF-36) as the most well-suited candidate endpoint[1].”   ✅#My2_cents   When it comes to the topic of aging and longevity, there are sometimes differences between purely academic research and treating physicians who are researchers and scientists at the same time.   ➡Personally, I don't think that the view of clinicians has ever harmed a research project. The last author, Evelyne Bischof, MD, PhD, is one of the leading examples of the “species” of clinician + scientist.   ➡The authors emphasize „The unique value of the SF-36 for evaluating healthspan metrics. The #SF36 is a 36-item survey developed based on the Medical Outcomes Study and has been used for over three decades in clinical trial settings[1].”   The risks of not including QoL are "neglecting critical components of healthy aging and healthspan that encompass “real world” functional ability and the human experience. Factors that provide individuals with autonomy and agency in life, such as mental health, social functioning, and limitations in daily activities, play a critical role in both the biological and psychological process of healthy aging[1].”   ➡I would like to add, that it also depends a little bit on the use cases. Literature reports benefits of using patient-reported outcome measures in clinical routine - but also highlights limitations such as shifting “focus of consultations; inaccurately estimate problems; raise unrealistic expectations...; inhibit patient–clinician interaction; lack clinically meaningful information; and not be suitable for all patients[2].”   ➡Nevertheless, QoL should be part of the standard repertoire in research in aging.   🆔References check my 1st comment  20240422-11728

Evaluation of effect of cooled haemodialysis on cognition in patients with end-stage kidney disease (ECHECKED) feasibility randomised controlled trial results Effect of Cooled Haemodialysis on Cognition in Patients with End-Stage Kidney Disease (ECHECKED) Study Overview This study looked at whether cooler haemodialysis can help improve brain function in patients with severe kidney disease. Cognitive issues are common in these patients, and we wanted to explore this potential solution. Study Design We randomly assigned 90 patients to receive either standard haemodialysis at 36.5 °C or a cooler version at 35 °C. The main focus was on changes in cognitive scores after 12 months. We also examined factors like patient recruitment, reasons for dropping out, and overall quality of life. Key Findings Out of 334 patients screened, 160 were eligible, but 99 chose not to participate, mainly due to extra study visits. Only 61 patients agreed to join, and 43 were randomly assigned to the two groups. 27 patients completed the trial, while others withdrew or could not attend due to the pandemic. The cooler dialysis was generally well tolerated, but there was no significant improvement in cognitive scores between the two groups. No serious side effects were reported during the study. Challenges and Learnings The COVID-19 pandemic impacted the study, increasing the dropout rate to 27%. Many patients were deterred by the extra visits required. This experience will guide future studies in this area to enhance recruitment and retention strategies. Trial Registration ClinicalTrials.gov Identifier: NCT03645733. Registered on 24/08/2018. Importance of Clinical Trials Clinical trials are essential for creating safe and effective treatments. They should be integrated into everyday medical practice. Our AI-driven platform, DocSym, combines clinical guidelines and research into a single, accessible source for healthcare providers. Enhancing Patient Care In today’s healthcare landscape, improving efficiency is vital. Our mobile applications facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient management. AI for Better Outcomes By utilizing AI, clinics can improve their workflows, enhance patient outcomes, and reduce reliance on paper. Discover more about our solutions at aidevmd.com. https://lnkd.in/gUMTC-cu #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Efficacy of delivery of care with Tele-continuous EEG in critically ill patients: a multicenter randomized controlled trial (Tele-cRCT study) study Efficacy of Tele-EEG in Critically Ill Patients Study Overview This study looked at the effectiveness of Tele-continuous EEG (Tele-cEEG) compared to Tele-routine EEG (Tele-rEEG) for critically ill patients. The main focus was on seizure detection, mortality rates, and functional outcomes. Study Details The research took place over three years in eight hospitals in Thailand. It involved critically ill patients aged 15 and older who were at risk for seizures. Patients received either: Tele-cEEG: monitored for 24-72 hours Tele-rEEG: monitored for 30 minutes The study tracked the outcomes at various times, including hospital discharge and up to one year later. Results Summary A total of 254 patients participated: 128 received Tele-cEEG and 126 received Tele-rEEG. The findings showed: Seizures were detected slightly more with Tele-cEEG (21.88%) compared to Tele-rEEG (14.29%), but not significantly. No significant difference in mortality rates was found between the two groups. Functional outcomes were similar for both groups. Conclusions Both Tele-cEEG and Tele-rEEG were feasible options. However, Tele-cEEG needs more EEG specialists and resources. While Tele-cEEG might help detect seizures better, the study was not strong enough to show a clear benefit in reducing death rates or improving recovery. For settings with limited resources, Tele-rEEG is a good starting point for screening patients at risk for seizures. If Tele-cEEG is available, it is the preferred method. Clinical Trial Registration This trial is registered with the Thai Clinical Trials Registry (TTCTR20181022002). Value of Clinical Trials Clinical trials are essential for developing safe treatments. Our AI-driven platform, DocSym, integrates clinical protocols and research to aid healthcare professionals. Streamlining Operations In healthcare today, efficiency is key. Our mobile apps help manage scheduling, treatment monitoring, and telemedicine, improving patient care management. Enhancing Workflow with AI Using AI technology, clinics can streamline operations, improve patient outcomes, and reduce paper usage. Learn more at aidevmd.com. https://lnkd.in/gdaytJpG #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

📣 Not registered yet? There is still time to join us for the 2024 #WSCSpotlight tomorrow! ⚕ Hosted by the Global Sepsis Alliance the very rich program offers 9 distinctive sessions, globally renowned #clinicians, #researchers, #experts, and thought #leaders will cover the need for early #diagnosis and treatment of #sepsis in surgical #patients, #data, #AI, and predictive modeling in sepsis, how hypervolemia increases the mortality rate in sepsis, the role of #biomarkers, detecting sepsis in ventilated patients, #pediatric sepsis, including the new ‘Phoenix Criteria’, as well as personalized approaches to sepsis management. ➡ Register for free & check out the full program here 👀: wscspotlight.org

While the research and policy communities await more real-world evidence on how well these drugs work at slowing cognitive decline, improving function, and delaying nursing home admission, other critical questions still must be answered. Who will get access to these medicines first? Will there be delays for patients in rural settings or for patients with other social disadvantages based on socioeconomic status and insurance status? Also, will our current approaches to diagnosis and treatment provide the same opportunity for all patients to benefit from the drugs? In other words, will use of the drugs be #effective, accessible, and widely available? https://lnkd.in/eb7QpGUa OM1, Inc.: Advancing Alzheimer’s Research with Cutting-Edge Healthcare Innovation OM1 is at the forefront of healthcare innovation, leveraging insights-driven technology and #data to revolutionize #personalizedmedicine, evidence generation, and RWE research. “We know that the pathogenesis of Alzheimer’s can begin decades before clinical symptoms emerge. And, while exciting, the new disease-modifying therapies entering the market for the first time only have a modest impact on a person’s disease journey if they are already in advanced cognitive decline,” said Carl Marci, MD, Chief Clinical Officer and Managing Director of Mental Health and Neuroscience at OM1. “This, combined with the fact there is no cure, makes early detection and intervention to boost neuro-resiliency in patients even more crucial.” Led by a diverse team of scientists, engineers, researchers, and clinicians with over 30 years of experience in RWD and RWE, OM1 boasts a Real-World Data Cloud encompassing over one million patients. This patient data network advances research by: – Facilitating clinical trial recruitment – Uncovering prescriber trends – Modeling health economics and clinical outcomes In addition to standard claims data, the dataset includes enriched clinical notes from over 17,000 patients within its national network of specialists treating Alzheimer’s patients. This comprehensive dataset provides deeper insights into patient journeys, enabling earlier intervention. https://lnkd.in/es8CueyJ Alzheimer's Association® #marketaccess #access #healthequity #sdoh #medicalaffairs #neurology #agitation #neuroscience #alzheimers #dementia #patientoutcomes #rwd #rwe #evidence #valuebased #payer #outcomesresearch #outcomes #patientjourney #healtheconomics #data #dataanalytics #bigdata #predictiveanalytics #realworldevidence #pharma #drugdevelopment #patientcentricity #healthcare #affordability #healthaffairs #heor

🎈 New review in Lancet Rheumatology exploring how digital sensors can strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis. ➡ Review link: https://lnkd.in/gQBQ_Z6Q Inflammatory arthritides (IA) encompass a group of diseases marked by joint inflammation, leading to significant, long-term challenges for those affected. As a chronic condition, IA demands ongoing management and can profoundly impact patients' lives. Witnessing my own family members struggle with IA underscores the urgent need for advancements in this field. Thus far, endpoints for IA trials rely mainly on self-reported data that doesn't capture aspects essential to the patients themselves. For example, it is hard to conceive how a quick walking test in a clinic is sufficient to monitor the disease progression. Our review explores  - Why has there been a lack of sensor-based digital monitoring tools to capture the disease characteristics essential to the patients? - How can we use digital sensors to improve the impact of IA clinical trials? - What must we do as a community to accelerate this process? Medicine moves slowly but we don't have to. I believe that by using modern machinery and computational tools, we should be able to improve future therapeutics that actually improve the quality of life for the IA patients. On a personal note, I have learnt a massive amount working with a team of amazing colleagues from medicine, wearables and machine learning including Dylan McGagh Kaiyang Song Andrew Creagh Sally Fenton, Wan-Fai Ng, Jennifer Goldsack, Will Dixon Aiden Doherty Laura Coates There is still a lot to do but we are moving one step closer. #Rheumatology #InflammatoryArthritis #DigitalHealth #ClinicalTrials #LancetRheumatology #HealthTech #RheumatoidArthritis #PsoriaticArthritis #AxialSpondyloarthritis #JuvenileIdiopathicArthritis #wearables

Don't miss the eIVF booth at this week's PCRS conference where you can learn more about the benefits of eIVF’s unified platform! 🚀 Why eIVF? Because you deserve a partner who not just understands the complexities of the fertility field but also provides solutions that push you towards success. eIVF is your gateway to revolutionizing your clinic's operations and patient care standards. 🌈 🔹 Cloud-Based Excellence: eIVF's cloud-enabled platform masterfully integrates a comprehensive suite of modules—scheduling, patient demographics, clinical data, embryology, andrology, eRX, along with online patient and donor portals—creating a streamlined and interconnected workflow. By seamlessly connecting every vital function, from e-prescribing to patient engagement, eIVF ensures a smooth, efficient, and comprehensive patient care journey.  🌐 🔹 Seamless Integration: Worried about transitioning? With eIVF, it's smooth sailing. Our expertise in EMR conversions ensures you can focus on what you do best - delivering exceptional patient care. 💡 🔹 Strategic Growth: Experience growth like never before with our strategic partnerships, proven to significantly increase patient conversions. 🚀 🔹 Continuous Innovation: Showcasing Fertility Vision - our latest feature providing 24/7 insights into your practice's vital areas, supporting informed decision-making and fostering success. 🎯 👉 Ready to take your practice to new heights? Visit our booth to schedule a demo and see how eIVF can redefine your clinic's future. Don't miss out on this opportunity to elevate your patient care and clinic operations. See you there! 🌟

"Several major challenges, including an ageing population and declining workforce and the implementation of recent breakthrough therapies for Alzheimer disease, are prompting a necessary rethink of how people with neurodegenerative dementias are diagnosed and medically managed. Digital health technologies could play a pivotal part in this transformation, with new advances enabling the collection of millions of data points from a single individual. Possible applications include unobtrusive monitoring that aids early detection of disease and artificial intelligence-based health advice. To translate these advances to meaningful benefits for people living with a disease, technologies must be implemented within a system that retains the physician expert as a central figure in decision-making. This Perspective presents a new framework, termed the Digitized Memory Clinic, for the diagnostic pathway of neurodegenerative dementias that incorporates digital health technologies with currently available assessment tools, such as fluid and imaging biomarkers, in an interplay with the physician. The Digitized Memory Clinic will manage people across the entire disease spectrum, from the detection of risk factors for cognitive decline and the earliest symptoms to dementia, and will replace the present paradigm of a pure ‘brick-and-mortar’ memory clinic. Important ethical, legal and societal barriers associated with the implementation of digital health technologies in memory clinics need to be addressed. The envisioned Digitized Memory Clinic aims to improve diagnostics and enable precise disease-tracking prognostication for individuals with memory disorders and to open new possibilities, such as precision medicine for prevention and treatment." stephen Wong https://lnkd.in/g5v7-q-f

📃Scientific paper: Use of hip- versus wrist-based actigraphy for assessing functional decline and disease progression in patients with motor neuron disease Abstract: Background Actigraphy has been proposed as a measure for tracking functional decline and disease progression in patients with Motor Neuron Disease (MND). There is, however, little evidence to show that wrist-based actigraphy measures correlate with functional decline, and no consensus on how best to implement actigraphy. We report on the use of wrist actigraphy to show decreased activity in patients compared to controls, and compared the utility of wrist- and hip-based actigraphy for assessing functional decline in patients with MND. Methods In this multi-cohort, multi-centre, natural history study, wrist- and hip-based actigraphy were assessed in 139 patients with MND (wrist, n =  97; hip, n =  42) and 56 non-neurological control participants (wrist, n =  56). For patients with MND, longitudinal measures were contrasted with clinical outcomes commonly used to define functional decline. Results Patients with MND have reduced wrist-based actigraphy scores when compared to controls (median differences: prop. active = − 0.053 [− 0.075, − 0.026], variation axis 1 = − 0.073 [− 0.112, − 0.021]). When comparing wrist- and hip-based measures, hip-based accelerometery had stronger correlations with disease progression (prop. active: τ  = 0.20 vs 0.12; variation axis 1: τ  = 0.33 vs 0.23), whereas baseline wrist-based accelerometery was better related with future decline in fine-motor function (τ = 0.14–0.23 vs 0.06–0.16). Conclusions Actigraphy outcomes measured from the wr... Continued on ES/IODE ➡️ https://etcse.fr/RJ7Yb ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you. #amyotrophiclateralsclerosis #als #charcot

Modulation of hormonal, metabolic, inflammatory and oxidative stress biomarkers in women with polycystic ovary syndrome following combined (resistant and endurance) training: a randomized controlled trail Modulation of Hormonal, Metabolic, and Inflammatory Biomarkers in Women with PCOS Study Overview Polycystic Ovary Syndrome (PCOS) is a common condition among women. Exercise is known to help, but there’s limited research on the best types of exercise. This study looked at how combined training (both resistance and endurance) affects various health markers in women with PCOS. Methodology We conducted a randomized controlled trial with 30 women aged around 24 years, who were divided into two groups. One group participated in a combined training program for eight weeks, while the other group did not. We measured several health indicators before and after the training, including: Fasting plasma glucose Insulin levels Cholesterol levels Hormones like testosterone and AMH Markers of oxidative stress and inflammation Key Findings After eight weeks of training, the group that exercised showed significant improvements: Reduced insulin levels Lower cholesterol and testosterone levels Improved insulin sensitivity However, other health markers did not show significant changes compared to the control group. Conclusions Combined training is an effective way to help manage PCOS symptoms. The recommended training intensity is 50%-70% of one-repetition maximum for strength and 60%-70% of target heart rate for endurance. More research is needed to optimize exercise protocols for PCOS patients. Trial Registration This trial is registered in the Iranian Registry of Clinical Trials (IRCT20130812014333N143). You can access it here. Enhancing Clinical Practice Clinical trials are essential for developing safe treatments. Our AI-driven platform, DocSym, combines clinical guidelines and research into one easy-to-use resource for healthcare professionals. Streamlining Healthcare Operations In today’s fast-paced healthcare environment, efficiency is key. Our mobile apps assist with scheduling, treatment monitoring, and telemedicine, making patient care simpler and more accessible. Improving Patient Outcomes By integrating AI, clinics can improve workflows, enhance patient outcomes, and reduce paperwork. Discover how we can support your practice at aidevmd.com. https://lnkd.in/gSGv45iG #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics